The global Natural Killer Cells Market is estimated to be valued at US$ 132.76 Mn in 2023 and is expected to exhibit a CAGR of 44.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Natural Killer (NK) Cells are a type of cytotoxic lymphocytes that play a major role in the rejection of tumor cells and cells infected by viruses. They can directly kill infected cells without prior activation. NK cells are being explored for adoptive cell therapy for cancer treatment.
Market key trends:
One of the major trends in the Natural Killer Cells market is the increasing focus on gene-edited NK cells. Gene editing techniques like CRISPR allow scientists to modify the genes of NK cells to enhance its cancer killing potential. Editing genes involved in the activation, proliferation and cytotoxicity pathways helps improve the persistence and anti-tumor activity of NK cells. This gives gene-edited NK cells an advantage over normal NK cells and is expected to boost their adoption in adoptive cellular therapies for cancer treatment.
Segment Analysis
The global Natural Killer (NK) cells market is segmented into thermal immunotherapy, immunotherapy, and adoptive cell transfer based on therapy. Among these, the adoptive cell transfer segment dominated the market in 2022 due to supportive research & funding for novel NK cell therapeutics. Adoptive cell transfer therapy utilizes ex vivo expanded autologous or allogenic NK cells to boost the body's immune response against cancer cells. This immunotherpay helps eliminate tumor cells.
Key Takeaways
The global Natural Killer Cells Market Growth is expected to witness high growth, exhibiting a CAGR of 44.% over the forecast period, due to increasing incidence of cancer globally. According to WHO, cancer burden has risen to 19.3 million new cases and 10 million cancer deaths in 2020.
Regional analysis
North America dominated the global market in 2022 and is expected to maintain its lead over the forecast period. This is attributed to advancements in genetic engineering and rising cancer prevalence in the US. The Asia Pacific region is anticipated to be the fastest-growing market due to rising healthcare investments and growing cancer research & immunotherapy development programs in major economies like China and India.
Key players
Key players operating in the natural killer cells market are GC Cell (GC Biopharma corp.), ImmunityBio, Inc., Nkarta, Inc., Takeda Pharmaceutical Company Limited, Sanofi S. A., Innate Pharma SA. These players are focused on research and development of various NK cell therapeutics for cancer treatment through collaborative programs and clinical trials. For instance, in June 2022, GC Pharma received approval from Ministry of Food and Drug Safety to initiate Phase 1/2 clinical trial of GC027, an allogenic Natural Killer cell therapy candidate, in patients with acute myeloid leukemia.
For more insights, Read- https://www.ukwebwire.com/natural-killer-cells-market-trends-size-and-share-analysis/
Comments
0 comment